Cargando…
A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer
To explore the antitumor effect of hypoxia-inducible factor-1α short hairpin RNA (HIF-1α shRNA) delivered by ultrasound targeted microbubble destruction (UTMD) and transcatheter arterial embolization (TAE) on rats with hepatic cancer. After the models of transplantation hepatoma were established, Wi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399560/ https://www.ncbi.nlm.nih.gov/pubmed/30911540 http://dx.doi.org/10.1155/2019/1937460 |
_version_ | 1783399784449572864 |
---|---|
author | Liao, Yangying Luo, Haibo He, Zhizhong Kuang, Yongpei Chen, Peifen Zhang, Xiuzhen Chen, Junjun Wen, Qirong Xie, Yuhuan Ding, Shangwei |
author_facet | Liao, Yangying Luo, Haibo He, Zhizhong Kuang, Yongpei Chen, Peifen Zhang, Xiuzhen Chen, Junjun Wen, Qirong Xie, Yuhuan Ding, Shangwei |
author_sort | Liao, Yangying |
collection | PubMed |
description | To explore the antitumor effect of hypoxia-inducible factor-1α short hairpin RNA (HIF-1α shRNA) delivered by ultrasound targeted microbubble destruction (UTMD) and transcatheter arterial embolization (TAE) on rats with hepatic cancer. After the models of transplantation hepatoma were established, Wistar rats were randomly divided into 4 groups: Control group, UTMD group, TAE group, and UTMD+TAE group. Contrast-enhanced ultrasound (CEUS) was used to monitor tumor size on day 14 after four different treatments. Western blotting and immunohistochemistry were applied to measure the protein level of HIF-1α and VEGF in the hepatic cancer tissue. In comparison with UTMD+TAE group (21.25±10.68 days), the mean survival time was noticeably shorter in the Control group and TAE group (13.02±4.30 days and 15.03±7.32 days) (p<0.05, respectively). There was no statistical difference between UTMD+TAE group and UTMD group of the mean survival time (p>0.05). In addition, our results proved that the tumor sizes in UTMD+TAE group were obviously smaller than those in other groups (p<0.05, respectively). By CEUS, we clearly found that the tumor size was the smallest on day 14 in the UTMD+TAE group. The western blotting and immunohistochemistry results proved that the protein levels of HIF-1α and VEGF in UTMD+TAE group were obviously lower than those in TAE group and Control group on days 7 and 14 (p<0.05, respectively). However, there was no statistical difference between UTMD+TAE group and UTMD group (p>0.05). In this study we tried to explore the antitumor effect through a combination of UTMD-mediated HIF-1α shRNA transfection and TAE on rats with hepatic cancer. Our results showed that UTMD-mediated HIF-1α shRNA transfection and TAE can obviously silence HIF-1α and VEGF expression, thereby successfully inhibiting the growth of the tumor. |
format | Online Article Text |
id | pubmed-6399560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-63995602019-03-25 A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer Liao, Yangying Luo, Haibo He, Zhizhong Kuang, Yongpei Chen, Peifen Zhang, Xiuzhen Chen, Junjun Wen, Qirong Xie, Yuhuan Ding, Shangwei Biomed Res Int Research Article To explore the antitumor effect of hypoxia-inducible factor-1α short hairpin RNA (HIF-1α shRNA) delivered by ultrasound targeted microbubble destruction (UTMD) and transcatheter arterial embolization (TAE) on rats with hepatic cancer. After the models of transplantation hepatoma were established, Wistar rats were randomly divided into 4 groups: Control group, UTMD group, TAE group, and UTMD+TAE group. Contrast-enhanced ultrasound (CEUS) was used to monitor tumor size on day 14 after four different treatments. Western blotting and immunohistochemistry were applied to measure the protein level of HIF-1α and VEGF in the hepatic cancer tissue. In comparison with UTMD+TAE group (21.25±10.68 days), the mean survival time was noticeably shorter in the Control group and TAE group (13.02±4.30 days and 15.03±7.32 days) (p<0.05, respectively). There was no statistical difference between UTMD+TAE group and UTMD group of the mean survival time (p>0.05). In addition, our results proved that the tumor sizes in UTMD+TAE group were obviously smaller than those in other groups (p<0.05, respectively). By CEUS, we clearly found that the tumor size was the smallest on day 14 in the UTMD+TAE group. The western blotting and immunohistochemistry results proved that the protein levels of HIF-1α and VEGF in UTMD+TAE group were obviously lower than those in TAE group and Control group on days 7 and 14 (p<0.05, respectively). However, there was no statistical difference between UTMD+TAE group and UTMD group (p>0.05). In this study we tried to explore the antitumor effect through a combination of UTMD-mediated HIF-1α shRNA transfection and TAE on rats with hepatic cancer. Our results showed that UTMD-mediated HIF-1α shRNA transfection and TAE can obviously silence HIF-1α and VEGF expression, thereby successfully inhibiting the growth of the tumor. Hindawi 2019-02-19 /pmc/articles/PMC6399560/ /pubmed/30911540 http://dx.doi.org/10.1155/2019/1937460 Text en Copyright © 2019 Yangying Liao et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Liao, Yangying Luo, Haibo He, Zhizhong Kuang, Yongpei Chen, Peifen Zhang, Xiuzhen Chen, Junjun Wen, Qirong Xie, Yuhuan Ding, Shangwei A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer |
title | A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer |
title_full | A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer |
title_fullStr | A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer |
title_full_unstemmed | A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer |
title_short | A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer |
title_sort | combination of utmd-mediated hif-1α shrna transfection and tae in the treatment of hepatic cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399560/ https://www.ncbi.nlm.nih.gov/pubmed/30911540 http://dx.doi.org/10.1155/2019/1937460 |
work_keys_str_mv | AT liaoyangying acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT luohaibo acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT hezhizhong acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT kuangyongpei acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT chenpeifen acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT zhangxiuzhen acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT chenjunjun acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT wenqirong acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT xieyuhuan acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT dingshangwei acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT liaoyangying combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT luohaibo combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT hezhizhong combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT kuangyongpei combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT chenpeifen combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT zhangxiuzhen combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT chenjunjun combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT wenqirong combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT xieyuhuan combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer AT dingshangwei combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer |